Jennifer Amengual – New Associate Editor for Blood Neoplasia!
Blood Journals Portfolio shared on LinkedIn:
”We are delighted to introduce Dr. Jennifer Amengual, new Associate Editor for Blood Neoplasia!
Dr. Amengual is an Associate Professor of Medicine at Columbia University Irving Medical Center and a physician-scientist whose research focuses on developing targeted therapies for patients with lymphoma.
Her work has advanced our understanding of epigenetic and transcriptional pathways in germinal center–derived B-cell and T-cell lymphomas, as well as strategies to predict, prevent, and treat post-transplant lymphoproliferative disorders.
Beyond her research, Dr. Amengual is a dedicated mentor and an active member of American Society of Hematology, contributing to programs such as CRTI, TRTH, and the Hematology Review Series.
She has also led impactful clinical trials through ETCTN/CTEP, SWOG, and investigator-initiated studies.
Please join us in welcoming Dr. Amengual to the Blood Neoplasia team.”
Stay updated with Hemostasis Today.
-
Feb 25, 2026, 14:07Sumedha Dash: Why Whole Blood is Rarely the Answer Anymore?
-
Feb 25, 2026, 14:05Patient Perspectives on HMB in Women with Very Rare Bleeding Disorders – EAHAD
-
Feb 25, 2026, 13:36Zoltan Nagy: Antibody Response Can Shift from Recognizing the Adenoviral Protein to Targeting PF4 in Rare VITT Cases
-
Feb 25, 2026, 13:08Sam K. Saha: Same Clot Against Fast and Slow Systems
-
Feb 25, 2026, 13:04Haykaz Muradyan: The Use of REBOA in Obstetric Haemorrhage
-
Feb 25, 2026, 12:53Jan Hartmann: NexSys Plasma Collection System Receives FDA Clearance
-
Feb 25, 2026, 12:45Zain Khalpey: Secondary Stroke Prevention as The Most Important Opportunity to Reduce Disability
-
Feb 25, 2026, 12:40Jeff June: Stroke Care Is Clinically Mature, Stroke Biology Is Still Evolving
-
Feb 25, 2026, 12:36Wolfgang Miesbach: Repurposing Metformin – From Sugar Control to Thrombus Control